… progressive disease in patients with multiple myeloma (MM), according to study findings …

… bispecific antibodies to patients with multiple myeloma and other malignancies, according to … ’s extensive not only in multiple myeloma and lymphoma, [but] also in … have many cancers other than multiple myeloma and lymphoma. We are going …

… and G-CSF in multiple myeloma patients undergoing autologous stem … patients.” In addition to multiple myeloma and a planned phase … 2025. In addition to multiple myeloma, GPC-100 is also … improve stem cell mobilization in multiple myeloma, sickle cell disease, …

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective options for patients.

… , Nadine Poormon was diagnosed with multiple myeloma, a rare blood cancer that … CAR T-cell therapy for multiple myeloma—a new treatment approach where … therapy without needing further treatment. “Multiple myeloma is incurable, so it is …

… incredibly important for [patients with multiple] myeloma. What these do is … their unique situation, their unique [multiple] myeloma, and what other comorbidities they … patients with relapsed/refractory multiple myeloma. J Clin Oncol. Published online …

… therapies continues to expand in multiple myeloma, lymphoma, and solid cancers, according … ’s extensive not only in multiple myeloma, lymphoma, [but] also in solid … have many cancers other than multiple myeloma and lymphoma. We’re going …

Panelists discuss how long-term CARTITUDE-1 data may change clinical practice by validating earlier use of ciltacabtagene autoleucel (cilta-cel) and informing personalized treatment strategies based on risk and disease biology.

… (EC) to treat newly diagnosed multiple myeloma (MM). The drug has been …

… bispecific use for patients with multiple myeloma.